𝛼-CD20 x 𝛼-CD40

First-in-Class Bispecific Platform

Flow Arrows
Chronic Treatment β†’ Disease Modifying Therapy

Efficient Frontier of Immune Reset

Immune Reset necessarily requires both B cell depletion of the peripheral, tissue and memory compartments as well as T cell inhibition to prevent autoreactive B cell activation.

Efficient Frontier of Immune Reset
𝛼-CD20 x 𝛼-CD40

A Deceptively Simple Idea with Profound Implications

CD20 & CD40 are validated powerful upstream targets on pathologic B & T cells, but simultaneous targeting remains unexplored due to theoretical safety concerns of dual inhibition

Flow Arrows

Clinically proven advancements in bispecific antibody technology allow safe unlocking of synergistic biology

Scientific Evolution

By pursuing the hard problem of transplantation tolerance, Diabetes Free, Inc. (DFI) has arrived at potentially disruptive solutions to the big problems in autoimmunity and oncology

First, DFI induced immune tolerance to Islet Transplantation as a functional cure of diabetes
Antigen Presenter x 𝛼-CD40
=
Immune Tolerance
Now, DFI is applying its transplantation rigor to autoimmunity & oncology
𝛼-CD20 x 𝛼-CD40
=
Immune Reset

Evolution of Immunomodulation Immune Reset

𝛼-CD20 x 𝛼-CD40 BsAb
 
1st Generation
B cell Depletion
CD19/CD20
2nd Generation
CD19
CAR-T
3rd Generation
T cell Engagers
CD19/20xCD3
Next Generation
𝛼-CD20 x
𝛼-CD40 BsAb
clinical outcome
Delayed Progression
Remission
Partial Remission
Curative Intent
safety
(csr)
circulating B cells depletion
tissue B cells depletion
β€”
memory B cells depletion
β€”
tcells: Tregs Λ„
β€”
β€”
β€”
tcells: Teff Λ…
β€”
β€”
β€”
macrophage / APCs depletion
β€”
β€”
β€”

Safe by Design

Absence of CD3+ T cell effector function against B cell targeting antigen prevents the possibility of CRS.

Immune Reset Curative Intent

Requires Both Humoral & Cellular Immunomodulation

Immune Reset

Pan Autoimmune Indication Strategy

Ambulatory IV Drug Enables Larger TAMs Relative to Cost & Complexity of CD19 CAR & CD19/20 Bi-CAR

Largest Autoimmune Indication TAMs

Rheumatoid Arthritis

Psoriasis

Multiple Sclerosis

Other

UC & Crohn's Disease

Atopic Dermatitis

T1D

Psoriatic Arthritis

SLE / LN /
SjΓΆgren’s

Legend

BsAb

𝛼-CD40

IND-enabled / submitted

Potential / BsAb Indication

Oncology Rationale

IMMUNE CLEARANCE of Malignant B cell Compartment

Loss of CD19/20 is a common escape mechanism, but co-expression of CD20 and CD40 may result in superior tumor clearance

CD20 CD40 co-expression in leukemias & lymphomas

CD20
CD40
DLBCL
High
High
CLL
Weak to Moderate
Moderate
Burkitt Lymphoma
High
High
Follicular Lymphoma
High
High
Marginal Zone Lymphoma
High
High
Mantle Cell Lymphoma
High
Moderate to High

Pipeline in a Platform

Therapy
Indications
Status
Monoclonal mAb
𝛼-CD40𝛼-CD40
Transplantation &
Multiple Sclerosis
IND-Enabled
IND-Enabling
Bivalent BsAb1
𝛼-CD40 x 𝛼-CD20
Autoimmunity (RA, SLE, SjΓΆgren's)
FIH Q4 2025
Tetravalent BsAb
𝛼-CD402 x 𝛼-CD202
Oncology (FL, MZL, MCL)
FIH Q1 2026

Legend

𝛼-CD20

𝛼-CD40

1. IP 2045 CoM

NB: Antibody graphics not representative of actual structure